# CJC-1295 vs Sermorelin: Two GHRH Analogs Compared

> CJC-1295 vs sermorelin: two GHRH-receptor agonists that differ mainly in duration. The long-acting DAC analog beside short-acting sermorelin, on the GH/IGF-1 axis, cited.

Same receptor, same axis, different clocks — what separates the long-acting analog from its short-acting class-mate.

## The same receptor, a different clock

CJC-1295 vs sermorelin is a comparison within one drug class. Both are GHRH-receptor agonists — synthetic analogs of the GHRH(1-29) sequence that stimulate the pituitary to release the body's own growth hormone, raising IGF-1 downstream [8]. Sermorelin is essentially synthetic GHRH(1-29) itself; CJC-1295 is that backbone modified for resistance and, in the DAC form, for duration [2][8].

The defining difference is half-life. Sermorelin is short-acting, cleared in minutes, with an effect that tracks the natural pulse. CJC-1295 DAC is long-acting, with a 5.8-8.1 day half-life and IGF-1 elevation persisting up to 28 days after multiple doses [1]. They occupy the same axis through the same receptor — they differ chiefly in how long the signal lasts, which is a pharmacokinetic distinction, not a difference in target.

## Where CJC-1295 sits among GHRH analogs

The class is small and well-characterized. It includes sermorelin (synthetic GHRH(1-29)), tesamorelin (the FDA-approved GHRH analog for HIV-associated lipodystrophy), and CJC-1295 (a research-stage long-acting analog) [8]. A 2025 Nature Reviews Endocrinology review describes the receptor signaling and the rationale for long-acting analog design across this class [8]. CJC-1295's position is defined by duration: it is the long-acting member, distinguished from sermorelin by the DAC albumin-conjugation strategy and from tesamorelin by its lack of regulatory approval for any indication.

## What the comparison can and cannot claim

The pharmacology is comparable; the evidence base is not symmetric. Sermorelin has a long clinical history and was an approved diagnostic and therapeutic agent; CJC-1295 has only early-phase PK studies and no completed efficacy program [1]. So while both act on the GH/IGF-1 axis, a head-to-head efficacy or safety comparison in healthy adults does not exist in the published literature. The honest comparison is mechanistic and kinetic — same receptor, different duration — not a ranked outcome.

The long-acting profile is a double-edged property. Sustained GHRH-receptor stimulation produces durable IGF-1 elevation [1], but it also means a single dose cannot be quickly reversed, which is part of why sustained GH/IGF-1 elevation carries the theoretical safety questions discussed on the [FAQ](/faq).

## The pulsatility question

A reasonable concern about any long-acting GHRH analog is whether continuous stimulation flattens the natural GH pulse. For CJC-1295, the published answer is that it does not: in healthy men, the frequency and magnitude of pulsatile GH secretion were unaltered after a single dose, even as basal and mean GH rose [3]. This is biologically notable because episodic GHRH delivery drives GH pulses more effectively than continuous infusion [6] — so a long-acting analog that preserves pulsatility behaves more favorably than a naive continuous-stimulation model would predict. Sermorelin, being short-acting, tracks the natural pulse by default, so the two reach a similar pulsatile endpoint by different routes.

## Which questions the comparison answers

For a reader deciding what the literature actually supports, the comparison resolves to a few clean facts. Both compounds act on the GHRH receptor and raise GH and IGF-1 [1][8]. CJC-1295 DAC does so for days from one dose; sermorelin does so briefly [1][2]. Neither has a head-to-head trial against the other. And one of the two — sermorelin — has regulatory history, while CJC-1295 remains unapproved for human use, a status detailed on the [FAQ](/faq). Anything beyond those facts is extrapolation the published record does not license.

---

A curated night-board of the CJC-1295 record — each study, kinetic figure, and honest gap lit in its own tile and weighed by what the literature can actually carry, with no clinic behind the board and nothing here dispensed or sold.